Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences
Leskela S,
Susanna Leskela,
Romero I,
Ignacio Romero,
Cristobal E,
Eva Cristobal,
Belén Perez‐Mies,
Belén Pérez-Mies,
Juan M Rosa-Rosa,
Rosa-Rosa JM,
Gutierrez-Pecharroman A,
Ana Gutierrez-Pecharroman,
Caniego-Casas T,
Tamara Caniego-Casas,
Almudena Santón,
Santón A,
Belén Ojeda,
Ojeda B,
Raquel López-Reig,
López-Reig R,
Palacios-Berraquero ML,
María L Palacios-Berraquero,
Ángel García,
García Á,
Javier Ibarra,
Ibarra J,
Sofía Hakim,
Hakim S,
Rosa Guarch,
Guarch R,
José A López-Guerrero,
López-Guerrero JA,
Poveda A,
Andrés Poveda,
José Palacios,
Palacios J
other
OA: closed
public-domain-us
⚙
AI-generated summary
by claude@2026-06, 2026-06-13
ⓘ
Mismatch repair deficiency (MMRD) is frequent in endometrioid ovarian carcinoma (18%) and clear cell carcinoma (2%), primarily driven by MLH1 promoter methylation in sporadic cases or germline mutations in Lynch syndrome, and is linked to younger age and increased tumor-infiltrating lymphocytes.
Abstract
Mismatch repair deficiency (MMRD) is involved in the initiation of both hereditary and sporadic tumors. MMRD has been extensively studied in colorectal cancer and endometrial cancer, but not so in other tumors, such as ovarian carcinoma. We have determined the expression of mismatch repair proteins in a large cohort of 502 early-stage epithelial ovarian carcinoma entailing all the 5 main subtypes: high-grade serous carcinoma, endometrioid ovarian carcinoma (EOC), clear cell carcinoma (CCC), mucinous carcinoma, and low-grade serous carcinoma. We studied the association of MMRD with clinicopathologic and immunohistochemical features, including tumor-infiltrating lymphocytes in EOC, the histologic type in which MMRD is most frequent. In addition, MLH1 promoter methylation status and massive parallel sequencing were used to evaluate the proportion of sporadic and Lynch syndrome-associated tumors, and the most frequently mutated genes in MMRD EOCs. MMRD occurred only in endometriosis-associated histologic types, and it was much more frequent in EOC (18%) than in CCC (2%). The most frequent immunohistochemical pattern was loss of MLH1/PMS2, and in this group, 80% of the cases were sporadic and secondary to MLH1 promoter hypermethylation. The presence of somatic mutations in mismatch repair genes was the other mechanism of MMRD in sporadic tumors. In this series, the minimum estimated frequency of Lynch syndrome was 35% and it was due to germline mutations in MLH1, MSH2, and MSH6. ARID1A, PTEN, KTM2B, and PIK3CA were the most common mutated genes in this series. Interestingly, possible actionable mutations in ERRB2 were found in 5 tumors, but no TP53 mutations were detected. MMRD was associated with younger age and increased tumor-infiltrating lymphocytes. Universal screening in EOC and mixed EOC/CCC is recommended for the high frequency of MMRD detected; however, for CCC, additional clinical and pathologic criteria should be evaluated to help select cases for analysis.
My notes (saved in your browser only)
Condition tags
endometriosis
MeSH descriptors
Biomarkers, Tumor
Carcinoma
Colorectal Neoplasms, Hereditary Nonpolyposis
DNA Mismatch Repair
DNA Repair Enzymes
Ovarian Neoplasms
Age Factors
Biomarkers, Tumor
Biomarkers, Tumor
Carcinoma
Carcinoma
Carcinoma
Carcinoma
Colorectal Neoplasms, Hereditary Nonpolyposis
Colorectal Neoplasms, Hereditary Nonpolyposis
Colorectal Neoplasms, Hereditary Nonpolyposis
Colorectal Neoplasms, Hereditary Nonpolyposis
Disease Progression
DNA Methylation
DNA Mutational Analysis
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
The paper's references may be in our DB but unresolved to
``paper_id`` (resolution happens at ingest when the cited DOI
matches a row we already have). Run the cross-source citation
reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-12T06:07:16.479679+00:00
- pubmed
- last seen: 2026-05-13T22:22:05.164793+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine